Summary Slide.png (107.16 kB)
Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
figure
posted on 2020-11-05, 10:30 authored by Aixin Shi, Panpan Xie, Lasse Lykke Nielsen, Trine Vang Skjøth, Xuemei He, Sine Pfeiffer HaugaardArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.